Effect on Hearing of Oral Valganciclovir for Asymptomatic Congenital Cytomegalovirus Infection

Congenital cytomegalovirus (CMV) infection is the leading nongenetic cause of congenital sensorineural hearing loss (SNHL). Hearing loss due to congenital CMV infection either has onset after the newborn period or shows progressive decline in auditory thresholds. Although 90% of the congenitally inf...

Full description

Saved in:
Bibliographic Details
Published in:Journal of tropical pediatrics (1980) 2011-04, Vol.57 (2), p.132-134
Main Authors: CIFTDOGAN, Dilek Yilmaz, VARDAR, Fadil
Format: Article
Language:English
Subjects:
Administration, Oral
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - therapeutic use
Biological and medical sciences
Cytomegalovirus
Cytomegalovirus - drug effects
Cytomegalovirus - isolation & purification
Cytomegalovirus Infections - congenital
Cytomegalovirus Infections - diagnosis
Cytomegalovirus Infections - drug therapy
Cytomegalovirus Infections - virology
Ganciclovir - analogs & derivatives
Ganciclovir - therapeutic use
General aspects
Hearing - drug effects
Hearing Loss, Sensorineural - congenital
Hearing Loss, Sensorineural - drug therapy
Hearing Loss, Sensorineural - virology
Humans
Infant
Infant, Newborn
Infectious diseases
Male
Medical sciences
Pharmacology. Drug treatments
Treatment Outcome
Viral diseases
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Congenital cytomegalovirus (CMV) infection is the leading nongenetic cause of congenital sensorineural hearing loss (SNHL). Hearing loss due to congenital CMV infection either has onset after the newborn period or shows progressive decline in auditory thresholds. Although 90% of the congenitally infected infants are asymptomatic at birth, evidence is accumulating that these infants are at risk for audiologic, neurologic and developmental sequelae. In symptomatically infected infants, ganciclovir therapy administered in the neonatal period prevents hearing deterioration. However, preventative therapy of asymptomatic congenital CMV disease is controversial. Here in, we reported a male newborn with asymptomatic congenital CMV with bilateral SNHL. Oral treatment with valganciclovir in patient resulted in progressive improvement of SNHL, which effectively reduced the CMV viral load and was well tolerated without apparent adverse effects.
ISSN:0142-6338
1465-3664
DOI:10.1093/tropej/fmq050